B. Purpose of the requirement:
The new requirement was implemented in UK legislation in order to:
1. Enhance the safety of trial subjects/patients by seeking to ensure that the licensing authority is promptly informed of such serious breaches, in order to take appropriate action in response to the breach and/or,
2. To take the information regarding serious breaches into account when assessing future applications for clinical trial authorisation, and applications for marketing authorisation, which include data from trials affected by serious breaches.
Current clinical trials
Not yet recruiting
Recruiting
Not yet recruiting
Not yet recruiting
Not yet recruiting
Active, not recruiting
Completed